Update: Bioheart Partnership With Stemlogix Leads to First in U.S. Combination Regenerative Medicine Treatment on Injured Horse

Tue Dec 4, 2012 11:15am EST

* Reuters is not responsible for the content in this press release.

  SUNRISE, FL, Dec 04 (Marketwire) -- 
Bioheart Inc. (OTCQB: BHRT) previously announced that its cGMP facility
would be utilized by Stemlogix to help promote regenerative medicine for
the veterinary market. Stemlogix has just announced the first ever
combination regenerative medicine treatment on a six-year-old Quarter
Reined Cow horse that suffered a significant injury to its distal
straight sesamoidean ligament. 

    "The facilities at Bioheart Inc. are top notch and we are excited to move
these new therapies for animals forward using state-of-the-art cGMP
laboratories. We are fortunate to have the support and expertise of the
Bioheart team," said Jason Griffeth, Chief Operating Officer of
Stemlogix, LLC. 

    To provide him with this groundbreaking treatment, two small fat samples
were taken from the base of his tail via a minimally invasive
lipoaspirate procedure. Fat tissue is the richest source of stem cells
for both human patients and animal patients. One of the tissue samples
was processed on-site to provide a same-day, point-of-care stem cell
treatment while the other tissue sample was sent to the cGMP laboratory
where the mesenchymal stem cells were isolated and expanded for three
weeks. A portion of his stem cells were also cryopreserved for future
use. 

    Bioheart's president and CEO, Mike Tomas said, "Bioheart is focused on
commercializing cell therapies for cardiac patients and has many years'
experience with a variety of different cell types. This partnership
allows us to utilize our existing laboratories and expertise to bring
these products to the veterinary market." 

    About Bioheart, Inc.

    Bioheart is committed to maintaining its leading position within the
cardiovascular sector of the cell technology industry delivering cell
therapies and biologics that help address congestive heart failure, lower
limb ischemia, chronic heart ischemia, acute myocardial infarctions and
other issues. Bioheart's goals are to cause damaged tissue to be
regenerated, when possible, and to improve a patient's quality of life
and reduce health care costs and hospitalizations. 

    Specific to biotechnology, Bioheart is focused on the discovery,
development and, subject to regulatory approval, commercialization of
autologous cell therapies for the treatment of chronic and acute heart
damage and peripheral vascular disease. Its leading product, MyoCell, is
a clinical muscle-derived cell therapy designed to populate regions of
scar tissue within a patient's heart with new living cells for the
purpose of improving cardiac function in chronic heart failure patients.
For more information on Bioheart, visit www.bioheartinc.com, or visit us
on Facebook: Bioheart and Twitter @BioheartInc. 

    About Stemlogix, LLC 

    Stemlogix high quality stem cell therapy and other regenerative medicine
therapies are impacting the lives of cats, dogs and horses around the
U.S. and in other countries. The company has developed a scientifically
validated method for harvesting stem cells from both fat tissue and bone
marrow for therapeutic use. The Stemlogix stem cell isolation processes
provide for consistent cellular products that are compliant with current
regulatory guidelines. Stemlogix has a highly experienced management team
with over 20 years combined experience in developing multiple stem cell
therapeutics for both human and animal use. In all of its products and
services, Stemlogix aims to provide the best cutting-edge regenerative
medical solutions, and seeks to provide companion animals and horses with
renewed health and vitality. The company has partnered with Butler Schein
Animal Health(TM), the leading companion animal health distribution
company in the U.S., who are demonstrating the ease and effectiveness of
the Stemlogix regenerative medicine treatments to veterinarians
nationwide. To learn more about Stemlogix, LLC and its wide range of
innovative regenerative medicine products please visit www.stemlogix.com,
send an email to info@stemlogix.com or contact your local Butler Schein
Animal Health(TM) representative.

    Forward-Looking Statements: Except for historical matters contained
herein, statements made in this press release are forward-looking
statements. Without limiting the generality of the foregoing, words such
as "may," "will," "to," "plan," "expect," "believe," "anticipate,"
"intend," "could," "would," "estimate," or "continue" or the negative
other variations thereof or comparable terminology are intended to
identify forward-looking statements.

    Forward-looking statements involve known and unknown risks, uncertainties
and other factors which may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Also, forward-looking statements represent our management's
beliefs and assumptions only as of the date hereof. Except as required by
law, we assume no obligation to update these forward-looking statements
publicly, or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if new
information becomes available in the future.

    The Company is subject to the risks and uncertainties described in its
filings with the Securities and Exchange Commission, including the
section entitled "Risk Factors" in its Annual Report on Form 10-K for the
year ended December 31, 2011, and its Quarterly Report on Form 10-Q for
the quarter ended September 30, 2012.

    

Media Contact: 
Rhonda Madaris
13794 NW 4th Street
Suite 212
Sunrise, FL 33325
Telephone 954-835-1500
Email: rmadaris@bioheartinc.com 

Copyright 2012, Marketwire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.